40 results about "Immunohis tochemistry" patented technology

The invention discloses a polypeptide that can be specifically combined with lung cancer cells and a preparation method and application thereof. The polypeptide specifically combined with lung cancer cells shows peptide library reducing screening by a bacterial virus so as to obtain bacterial virus clone specifically with lung cancer; the bacterial virus clone having stronger affinity with lung cancer is identified by Elisa and an immunohistochemical method; and sequencing is sent so as to obtain a 12 polypeptide, and the amino acid sequence is shown as SEQ ID NO: 1. The 12 polypeptide screened by the invention not only has the advantages of traditional antibody molecule but also has small molecular weight, strong penetrating power and easy arriving to tumor tissue; the 12 polypeptide has good tumor targeting effect and more sensibility of tumor diagnosis, and can be used for preparing a kit for tumor diagnosis and drug for curing tumors.

The method of the invention pertains to determining the signal transduction activity in a tissue section by immunohistochemistry techniques. The expression level of the receptor of interest is determined as well as the expression levels of one or more effector molecules of the receptor signal transduction pathway. Furthermore a combined ratio of expression levels of effector molecules in subcellular compartments with the receptor expression was found to have prognostic significance.

The invention belongs to the technical field of cell secretion extraction, and discloses a method for extracting exosome derived from human hair follicle dermal papilla cells (DPC-Exos). The method isas below: identifying DPC-Exos by controlled resistance pulse sensing (TRPS) analysis, electron microscopy and Western Blot; and adding the DPC-Exos to a culture medium of human hair follicle outer root sheath cells (ORSCs) cultured in vitro. The DPC-Exos are identified to be about 105 nm in diameter and expressing tumor susceptibility gene (TSG) 101, differentiation cluster (CD) 9 and CD63; DPC-Exos promote proliferation and migration of human ORSCs, and mRNA and protein levels of beta-catenin and Sonichedgehog (Shh) in ORSCs are detected to be up-regulated after treatment; transdermal injection of DPC-Exos accelerates an HF growth phase of mice and delays the occurrence of regression. Immunohistochemical analysis shows that the expression levels of beta-catenin and Shh are up-regulatedin the hair follicles of an experimental group. DPC-Exos help regulate the growth and growth cycle of the HF and provide a new potential for the treatment of clinical hair loss.

The invention provides a recombinant lentiviral vector containing ubiquitin-specific protease gene USP39-shRNA (short hairpin ribonucleic acid) and application thereof. The test proves that expression of USP39 in breast cancer tissue is obviously higher than that in normal breast tissue; the immunohistochemical detection confirms that the expression of USP39 in the breast cancer tissue is obviously higher than that in normal breast tissue; the immunohistochemical detection confirms that expression of USP39 protein in the breast cancer tissue is obviously higher than that in para-carcinoma tissue; siRNA (small interfering ribonucleic acid) is designed in a breast cancer cell system to interfere the expression of the USP39; it is found that proliferation of breast cancer cell after reducing the USP39 is obviously restrained; the cell apoptosis ratio is obviously improved; the cell ratio at the G1 stage is increased; the cell ratio at the S sage is reduced; and the clonality of the cell is obviously reduced. The test proves that the USP39 has an important role in facilitation of development of the breast cancer; and theoretical and experimental basis is provided for preparation of a drug for preventing and treating the breast cancer by the lentiviral vector containing USP39-shRNA.

By adopting methods of fluorescent quantitation PCR, fluorescent quantitation RT-PCR, HBV DNA quantitation, HBsAg quantitation, HBeAg quantitation, cccDNA quantitation, Northern blot, Southern blot, Western blot, immunohistochemistry, and the like in the research and using the maintenance dose within the treating dose range for a long time (30-60 days), supernatant HBV DNA HBsAg HBeAg cultured by HepG-2.2.15 cells can completely disappear, HBsAg, HBeAg, HBcAg, and the like in the cells are completely turned to be negative, HBV DNA is in a high inhibited state, HBV cccDNA is completely negative, fluorescent quantitation RT-PCR detection finds that the mRNA for expressing HBsAg and HBcAg antigens in the cells is completely negative, and in addition, the curative effect of the atabrine is 30 times that of lamivudine as a first-line drug for resisting HBV in current clinic. In order to illustrate the action mechanism of the atabrine and the pyronaridine as a drug belonging to the same kind with the atabrine, an HBV genome is divided into 3 segments which are respectively inserted into an Xb1 position on a luciferase report carrier PGL3, a multifunctional microplate reader detects and finds that the light production value of the luciferase is remarkably reduced, which shows that the molecules of the atabrine and the pyronaridine as a drug belonging to the same kind with the atabrine can be nonspecifically combined with the HBV DNA in the cells, thereby inhibiting the copying of the virus and ensuring that the HBV DNA content of the virus in cells copied by the filial generation is reduced till to disappear. The patent requires protecting the application of 3 linked benzyl structures (named as ethyleneimine) and radicals such as CH3O-,-NH-, CL-, and the like for resisting HBV virus in clinic.

The invention belongs to the technical field of biomedicine, and particularly discloses an application of an FLT3LG protein to preparation of lung adenocarcinoma postoperation and prognosis evaluationreagents or kits. According to the application, the FLT3LG protein is taken as a marker to detect lung adenocarcinoma tissue specimens through an immunohistochemical method and judge the prognosis ofthe lung adenocarcinoma patients; the FLT3LG protein has high expression in the lung adenocarcinoma and has low expression in para-carcinoma tissues; the expression level of the FLT3LG protein in thelung adenocarcinoma is related to the survival of the patients; and the high-expression patients are bad in prognosis and short in survival. The expression level of the FLT3LG protein is not only related to the total survival of the lung adenocarcinoma patients, but also related to the disease-free survival of the patients, and the patients, the FLT3LG protein of which has high expression, have recurrence or metastasis earlier; and serving as a lung adenocarcinoma postoperation and prognosis marker, the FLT3LG protein has a wide application prospect and a relatively large social benefit.

The invention provides a folding dyeing frame, a horizontal incubation box and a using method. The folding dyeing frame comprises a plurality of clamping plates, wherein the plurality of clamping plates are folded in a zigzag shape, a foldable first connecting piece is arranged between every two adjacent clamping plates, empty grooves used for containing slides are formed in the clamping plates, transverse ribs used for supporting the slides are arranged at the rear ends of the empty grooves at intervals, blocking piece sets used for clamping the slides are arranged at the front ends and the rear ends of the empty grooves, and each blocking piece set comprises two baffles which are located on the two sides of the lower end of the corresponding empty groove respectively. According to the invention, the rapid switching of horizontal incubation and vertical repair washing processes in the immunohistochemistry experiment process is realized, the time is saved, the operation is convenient,and the sample treatment efficiency is improved.

Repression of CD36 vasculature in stromal tissues surrounding a pre-cancerous lesion provides is indicative of increased risk of subsequent progression to invasive cancer. Methods of assessing progression risk by measuring the abundance of CD36 vasculature in stromal tissues surrounding a precancerous lesion are provided, useful for various cancer types, including for assessing the risk of DCIS progression to breast cancer. Immunohistochemical analysis methods and diagnostic thresholds are provided, as well as associated methods of treatment and diagnostic kits.

The invention provides a pathological immunohistochemistry wet box. The box comprises a box body, wherein the box body is hollow and is provided with an upward opening; a plurality of connecting grooves are formed in the front side wall of the box body; the plurality of connecting grooves are arranged at equal intervals in the left-right direction; the connecting groove is provided with an upwardopening; a plurality of supporting parts are arranged on the inner side of the rear side wall of the box body; the supporting part is arranged corresponding to the connecting groove. The box also comprises a slide, wherein the front end of the slide is connected to the supporting part; the rear end of the slide penetrates through the connecting groove and extends to the outer side of the box body;a pressing block is further arranged on the connecting groove; the pressing block is matched with the connecting groove; protruding sliding blocks are arranged on the left side and the right side ofthe pressing block respectively. Sliding grooves corresponding to the sliding blocks are formed in the left side wall and the right side wall of the connecting groove respectively, the sliding blocksare in sliding fit with the sliding grooves in the vertical direction, the cover body covers an opening in the upper end of the box body and is provided with a plurality of sets of liquid adding holes, each set of liquid adding holes corresponds to one slide, and a liquid outlet communicated with the interior of the box body is formed in the bottom of the box body.

We present a new method to automatically sample the tumour/stroma interface zone (IZ) from microscopy image analysis data. It first delineates the tumour edge using a set of explicit rules in grid-subsampled tissue areas; then the IZ of controlled width is sampled and ranked by the distance from the edge to compute TIL density profiles across the IZ. From this data, a set of novel Immunogradient indicators are computed to reflect TIL “gravitation” towards the tumour. We applied the method on CD8 immunohistochemistry images of surgically excised breast and colorectal cancers to predict overall patient survival. In both patient cohorts, we found strong and independent prognostic value of the Immunogradient indicators, outperforming methods currently available. We conclude that data-driven, automated, human operator-independent IZ sampling enables precise spatial immune response measurement in the tumour/host interaction frontline for prediction of disease and therapy outcomes.

The invention relates to the technical field of immunohistochemical staining, in particular to a reagent bottle capable of controlling dropping liquid quality, which comprises a reagent bottle body, the reagent bottle body comprises a reagent bottle lower bottle body and a reagent bottle upper bottle body, the lower side of the reagent bottle body is provided with the reagent bottle lower bottle body, and the upper side of the reagent bottle lower bottle body is provided with a reagent bottle opening; the outer wall of the reagent bottle opening is provided with a connecting external thread, the upper side of the reagent bottle opening is provided with a bottle opening mounting end, the upper side of the reagent bottle body is provided with the reagent bottle upper body, and the reagent bottle upper bottle body comprises a needle head connecting seat and a needle head body; and the needle head connecting base is arranged at the position, corresponding to a bottle opening installation end, of the lower side of the reagent bottle upper bottle body, and a limiting installation plug is installed at the bottom of the needle head connecting base. On the whole, the device can greatly reduce the implementation complexity and cost, completely eliminate cleaning and switching operation during switching of different kinds of liquid and improve the working efficiency. Operation time is greatly shortened.

Ultrasound systems and methods are provided using mass characterization frequency methods that provide for predicting benign or malignant lesions, a response to treatment, tumor grading, and/or the expressions of immunohistochemical biomarkers, which are currently used for breast cancer classification and hormone therapy determination. The systems and methods are based on the shear wave parameter, mass characteristic frequency. The status of malignancy, treatment response, grade, and/or each immunohistochemical biomarker may be determined based on a corresponding mass characteristic frequency threshold.

An immunohistochemical microchromatometer has a transparent sheet as base body, on which there is a transparent chromatic band from light colour (tan) to dark colour (tawny), which are graduted. Said microchromatometer can be put in eye lens of microscopic to provide a colour reference to judge the immunohistochemical stain result. It can be made up by photography, copy and colour print.